Detalhe da pesquisa
1.
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.
N Engl J Med
; 387(2): 120-131, 2022 07 14.
Artigo
Inglês
| MEDLINE | ID: mdl-35658005
2.
Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity.
J Biol Chem
; 298(2): 101556, 2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34973338
3.
High-dose alectinib for RET fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial.
Contemp Oncol (Pozn)
; 27(4): 217-223, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-38405208
4.
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Lancet Oncol
; 22(7): 959-969, 2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-34118197
5.
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
N Engl J Med
; 378(22): 2078-2092, 2018 May 31.
Artigo
Inglês
| MEDLINE | ID: mdl-29658856
6.
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
J Natl Compr Canc Netw
; 19(8): 915-921, 2021 04 20.
Artigo
Inglês
| MEDLINE | ID: mdl-33878726
7.
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(3): 387-397, 2020 03.
Artigo
Inglês
| MEDLINE | ID: mdl-32035514
8.
COPD-dependent effects of genetic variation in key inflammation pathway genes on lung cancer risk.
Int J Cancer
; 147(3): 747-756, 2020 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31709530
9.
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Cancer
; 126(22): 4867-4877, 2020 11 15.
Artigo
Inglês
| MEDLINE | ID: mdl-32914866
10.
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 377(9): 829-838, 2017 08 31.
Artigo
Inglês
| MEDLINE | ID: mdl-28586279
11.
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.
Invest New Drugs
; 38(2): 457-467, 2020 04.
Artigo
Inglês
| MEDLINE | ID: mdl-31065954
12.
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Lancet Oncol
; 19(12): 1654-1667, 2018 12.
Artigo
Inglês
| MEDLINE | ID: mdl-30413378
13.
Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.
Br J Cancer
; 118(1): 38-42, 2018 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29149104
14.
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Lancet
; 389(10066): 255-265, 2017 01 21.
Artigo
Inglês
| MEDLINE | ID: mdl-27979383
15.
Rociletinib in EGFR-mutated non-small-cell lung cancer.
N Engl J Med
; 372(18): 1700-9, 2015 Apr 30.
Artigo
Inglês
| MEDLINE | ID: mdl-25923550
16.
Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
Curr Treat Options Oncol
; 19(11): 53, 2018 09 10.
Artigo
Inglês
| MEDLINE | ID: mdl-30203184
17.
The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Future Oncol
; 14(18): 1875-1882, 2018 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-29536761
18.
Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer.
Curr Treat Options Oncol
; 18(6): 36, 2017 06.
Artigo
Inglês
| MEDLINE | ID: mdl-28534251
19.
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Lancet Oncol
; 17(11): 1497-1508, 2016 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-27745820
20.
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
Lancet Oncol
; 17(2): 234-242, 2016 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-26708155